Managing Bone Health in Breast Cancer
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists(2023)
Abstract
Objective: Osteoporosis is a common condition that can be caused or exacerbated by estrogen deficiency.Methods: This narrative review will discuss optimizing bone health in the setting of adjuvant endocrine treatments for hormone receptor-positive breast cancer and the current use of anti-resorptive agents as adjuvant therapy and as bone modifying agents.Results: Adjuvant endocrine treatments for hormone receptor-positive breast cancer (tamoxifen and aromatase inhibitors) affect bone health. The exact effect depends on the agent used and the menopausal state of the woman. Antiresorptive medications for osteoporosis, bisphosphonates and denosumab, lower the risk of bone loss from aromatase inhibitors. Use of bisphosphonates as adjuvant treatment in breast cancer, regardless of hormone receptor status, is increasing because of benefits seen to cancer relapse and survival.Conclusion: Optimizing bone health in women with breast cancer during and after cancer treatment is informed by an understanding of breast cancer treatment and its skeletal effect.(c) 2022 AACE. Published by Elsevier Inc. All rights reserved.
MoreTranslated text
Key words
breast cancer,osteoporosis,aromatase inhibitor,bisphosphonate,denosumab,estrogen,Introduction
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined